Company
Biogen Inc
NASDAQ:BIIB
Biogen Inc is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia.
60 stories
Archive
Fuller Treacy Comment of the Day - Ford Takes $3.6 Billion Hit for Following the Tesla Playbook, and more...
Comment of the Day18th July 2023Eoin TreacyJul 19Video commentary for July 18th 2023A link to today's video commentary is posted in the Subscriber's Area.Some of the topics discussed include: US banks rebound, Dow Industrials and Transporta
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drug
The company expects sales to decline by mid-single digit percentages in 2023 after they fell nearly 7% to $2.54 billion in the fourth quarter
Roche Alzheimer's failure good news for rivals, analysts suggest
Roche said while there had been some level of beta-amyloid removal it was lower than expected
Biogen and Alzheimer's drug development companies surge on positive clinical data
Biogen surged 35% to US$267.80 in the five days to Friday following the news
Archive
US stocks lose steam at the close, Dow's winning streak ends
The S&P 500 lost 0.30% to sit at 4,779 points while the Dow sank 0.25% to finish at 36,398 points and the Nasdaq closed at 15,742 points for a 0.16% retreat on the day
FDA officials should resign over 'reckless' approval of Biogen Alzheimer’s drug, says US consumer rights group
Special interest group Public Citizen said in an open letter that the FDA should have rejected the drug and that its surprise approval "raised false hope for millions of Alzheimer’s disease patients"
Biogen's hefty price tag for new drug forecast to spark Alzheimer's research resurgence
News of the approval gave a boost to other companies developing Alzheimer’s treatments
Investments and investor services
Tiziana Life Sciences: US investment bank restates its US$8 price and 'buy' recommendation after double dose of good news
“Despite a recent pullback in the shares…we continue to like the risk-reward set-up," said B Riley Financial in a note to clients
Biogen to produce first therapy for Alzheimer’s if FDA approves next year
Aducanumab aims at reducing the clinical decline of the disease rather than the underlying cause
India Globalization Capital stock pops after CBD-based Hyalolex drops for Alzheimer’s patients launches in Puerto Rico
The company is holding a doctor-patient education conference on March 30 in San Juan to talk to patients and their families about how Hyalolex is a 'gentler treatment journey' for Alzheimer’s patients
Investments and investor services
LATE MOVERS: Viacom rises, AT&T falls as companies reach agreement over DirecTV
Also making moves were Apple, Biogen, Vale and Tesla
Investments and investor services
LATE MOVERS: Investors snack on Apple and chip stocks; Nike trips on 3Q results
Also making moves were Nike, Darden Restaurants, Micron and Conagra
LATE MOVERS: Salesforce.com falls after delivering disappointing 1Q outlook
Kraft Heinz shares picked up traction after a Morgan Stanley upgrade
Biogen tops 3Q estimates with Spinraza sales leading the charge
The success of Spinraza helped to offset decreased demand for its multiple sclerosis treatment Tecfidera
Neurotrope and Anavex are 'making progress' with Alzheimer's programs, says Maxim Group
Experts are optimistic biotechs may be turning the corner on the mind-robbing disease after years of failure
PRE-MARKET MOVERS: Xilinx Inc and AMD race up in pre-market after quarterly earnings; Biogen also booming
On a day where tech stocks are seen falling following Facebook results; Qualcomm Inc was another stock bucking the trend, with shares up
Biogen ups 2018 profit and revenue guidance after second-quarter earnings and revenue beat expectations
The Nasdaq-listed firm said its earnings for the quarter rose to US$867mln, or US$4.18 per share, up from US$863mln, or US$4.07 per share in the year-earlier period
Investments and investor services
Small-Cap Snapshot: Black Box wins US$10mln contract after issuing a bankruptcy warning
The tech company warned investors earlier this week that it was cash-strapped and may soon file for bankruptcy
PRE-MARKET MOVERS: Biogen shares blasting higher after positive Alzheimer’s trial results, but PriceSmart Inc takes a bath
Also in the frame before the bell was Aegean Marine Petroleum Network Inc and Wells Fargo & Co
Biogen expands neurology portfolio, acquires Phase 2 asset for acute stroke in US$377mln
Japanese company TMS' drug TMS-007 is designed to break down blood clots and prevent inflammation
Biogen to buy schizophrenia drug from Pfizer for up to US$590mln
PF-04958242 helps the central nervous system to send and receive ‘messages’, and Biogen is looking to take it through Phase IIb trials later this year
Investments and investor services
FTSE 100 can’t hold gains and closes in red as sterling firms
Britain's blue-chip benchmark closed down over nine points, or 0.13% to 7,214..
Biogen and AbbVie halt sales of Zinbryta multiple sclerosis drug due to safety concerns
Biogen and AbbVie have halted sales of the multiple sclerosis treatment following several reports of brain inflammation in people who took the drug
Biogen heads higher as fourth-quarter revenues and 2018 guidance top expectations
Biogen’s recently-launched spinal muscular atrophy treatment, Spinraza, helped to push revenues in the final three months of 2017 up by 15% to a record US$3.31bn
Bioverativ soars as it agrees to be taken over by Sanofi for US$11.6bn
Bioverativ shares jumped in pre-market trade, but Sanofi was the worst performer on France’s CAC 40, with analysts calling the deal expensive
Acorda Therapeutics shares jump on media reports of takeover interest from Biogen and others
The speculation comes after Acorda on Thursday provided preliminary guidance for its 2017 sales to be US$542mln, an increase of approximately 10% from 2016 but below the consensus estimate for US$568mln
Alkermes and Biogen to develop and commercialise ALKS 8700 for relapsing forms of MS
They are targeting to make a New Drug Application (NDA) for ALKS 8700 in 2018
Biogen shares advance after Morgan Stanley note and positive data
Biogen Inc today received a thumbs up from broker heavyweight Morgan Stanley
Biogen lifts full year guidance after second quarter results beat forecasts
Sales of spinal muscular atrophy drug Spinraza boosted Biogen's second quarter revenue
IXICO expands Assessa PML platform pilot to include pharmacovigilance
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
US stocks give back early gains to close lower on healthcare scare
US equities fell on Thursday, as initially buoyant stocks came off on the back of falls by utilities and a budgetary shock for the healthcare sector
Forward Pharma shoots up after US$1.25bn Biogen licensing deal
Biogen has agreed to pay US$1.25bn in cash to licence all of Forward’s intellectual property
Biogen boosts Alzheimer's hope with trial data
Gradually increasing the dose rather than starting at a high level appeared to cause less risk of brain swelling
US stocks close Friday with record highs as Trump rally rolls on
Wall Street stocks finished the week with another round of record highs as the sharp rally triggered by Donald Trump’s surprise presidential victory showed no signs of easing
Biogen and Ionis Pharma surge as Spinraza stars in trial
Motor function of children affected with spinal muscular atrophy (SMA) improved significantly
GW Pharma still has the legs to get over a tenner, but pick your entry point
Ideally you are looking at dips to the 50-day line at £6.29 - Zak Mir.
GW Pharmaceuticals data the "most convincing so far", says City heavyweight
Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
Biogen completes FDA application for muscle wasting drug
Biogen also plans to submit a Marketing Authorization Application to the European Medicines Agency.
Morgan Stanley hired for GW Pharmaceuticals bid parade
Analysts say the drug has the potential to deliver annual sales of around US$800mln.
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
Biogen tops Wall Street estimates for quarter
Biogen shares gain nearly 5% after the company beats estimates with its first quarter earnings
Wall Street shares seen higher with spotlight on earnings
Wall Street shares are seen opening slightly higher with earnings again in focus and after US markets closed up on Wednesday.
Biogen surges as fourth-quarter results top estimates
Results were helped by sales of the company’s most important multiple sclerosis drug, Tecfidera
Wednesday’s trending – Apple, oil and biotech
There were some big names taking a hit on Wednesday shedding light on the state of the global economy and none bigger than Apple...
Wall Street slides as biotech, commodities weigh; Biogen, TripAdvisor sink
U.S. stock indexes fell Friday as investors dumped shares of biotechnology companies after disappointing results from Biogen and as materials and energy stocks continued to lag. The S&P 500 (INDEXSP:.INX) slid 1.1 percent to 2,077.95 at
Wall Street poised to halt 3-day rout on strong earnings from Amazon, Visa, Starbucks
U.S. stock-index futures rose today after three straight days of losses as Amazon, Visa and Starbucks beat expectations. Nasdaq-100 futures rose 0.2 percent to 4,629. S&P 500 futures edged up 0.1 percent to 2,100, while those for the Do
Concerns over next phase of Niogen's Alzheimer candidate putting pressure on share price
Now, Cowen analyst Mark Schmidt, who set a price target for Biogen in the range of US$425-US$500 because of the Phase 1b’s results’ success, recently noted that as impressive as those results were the 6mg cohort "had not yet dif